BMRN News 60.89 Biomarin Pharmaceutical Inc (BMRN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biomarin Pharmaceutical Inc (BMRN) 60.89 $BMRN

How Are Orphan Drugmakers Faring in the Great Biotech Downturn?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
There is little debate that we are now in the throes of a general market correction. And because health-care and biotech stocks were the best performers over the past few years, they are being hit particularly hard in this downturn. That said, we...

Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.

BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET
GlobeNewswire - Wed Apr 16, 7:15AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, at 5:00 p.m. ET to discuss first quarter 2014 financial results and provide a general business update. The conference call will be accessible via the internet from the company's website.

Good News for BioMarin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 6:05PM CDT
The FDA has extended Kuvan's marketing exclusivity period.

Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Tue Apr 15, 10:15AM CDT
On Monday, April 14, 2014, the NASDAQ Composite ended at 4,022.69, up 0.57%, the Dow Jones Industrial Average advanced 0.91%, to finish the day at 16,173.24, and the S&P 500 closed at 1,830.61, up 0.82%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, while the same has fallen by 1.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free technical research on ONVO, BMRN, VRTX and SPPI can be downloaded upon signing up at:

Shares of BMRN Down 22.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 14, 11:02AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 1 month, BioMarin Pharmaceutical has returned 21.96% as of today's recent price of $59.08.

Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver
PR Newswire - Mon Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DIS, WAG, BMRN, CSIQ, and MNKD.

FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets
GlobeNewswire - Mon Apr 14, 7:08AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that the Food and Drug Administration (FDA) granted KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets a six-month pediatric exclusivity extension. The FDA action extends KUVAN's market exclusivity to June 2015 and is based on studies submitted in response to a written request by the FDA to investigate the use of KUVAN in pediatric patients from birth to age 6. KUVAN formulated as Tablets and Powder for Oral Solution, is the first and only FDA-approved medication for PKU to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet.

Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

'Mad Money' Lightning Round: I Don't See a BioMarin Rally
at The Street - Fri Apr 11, 5:00AM CDT
Cramer likes Service Corp. over Carriage Services and Magnum Hunter Resources over Swift Energy.

Jim Cramer's 'Mad Money' Recap: Blame China, Greece for the Meltdown
at The Street - Thu Apr 10, 7:24PM CDT
While everything went right in America, everything was going wrong in the rest of the world -- and that apparently makes all the difference, Cramer says.

Downtrend Call Working As BioMarin Pharmaceutical Stock Falls 16.0% (BMRN)
Comtex SmarTrend(R) - Mon Apr 07, 9:56AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 1 month, BioMarin Pharmaceutical has returned 16.01% as of today's recent price of $63.58.

The AACR Annual Meeting May Move These 2 Stocks
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 07, 8:43AM CDT
Markets slid into the weekend, sending the majority of stocks lower. But  Myriad Genetics and Pfizer may see investor interest return after presentations at the American Association for Cancer Research meeting. Let's look at why the confab...

Look for Shares of BioMarin Pharmaceutical to Potentially Rebound after Yesterday's 3.17% Sell Off
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $65.35 to a high of $68.08. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $66.08 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Clinical Outsourcing Strategies Discussed at the Silicon Valley BioTalks Now Available Online
PRWeb - Mon Mar 31, 2:42AM CDT
Outsourcing experts from Onyx Pharmaceuticals, San Francisco State University (SFSU), BioMarin Pharmaceutical, and Clinovo discussed the topic 'Manage In-house and Outsourced Clinical Trials: Vendor Selection, Project Coordination, and Resource Management' at the eighth Silicon Valley BioTalks.

Biomarin Pharmaceutical (BMRN) Showing Signs Of Being A Roof Leaker
at The Street - Thu Mar 27, 10:02AM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate

Good News for Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:30PM CDT
The independent DMC has recommended the continuation of Catalyst Pharma's phase III study on Firdapse.

Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma
PR Newswire - Wed Mar 26, 10:55AM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the same has fallen by 1.64% in the last one month. Investor-Edge has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on BCRX, SPPI, BMRN, and VRTX can be downloaded upon signing up at:

Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 82

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 219

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 137

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 105

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
TD Pledges $2 Billion to Financial Strength by 2036

Updated Category News Views 66

A Longer-Term Bet on Household Resilience A bank’s community budget rarely grabs the market by the collar, but TD’s new target deserves more than a polite nod. The bank says it will direct $2 billion, or US$1.4 billion, toward helping people build financial strength across North America over the next decade. That is a sizable commitment, even for an institution with...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 67

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 64

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 104

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 67

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 119

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Impact of Tariff Uncertainty on Canada

Updated Category News Views 274

Revisiting Canada's Economic Outlook Amid Tariff Uncertainty The Canadian economy has faced various challenges recently, but the specter of global tariff uncertainty looms larger this year. According to recent insights, there is a subdued growth expectation as businesses and consumers alike brace for the ripple effects of trade tensions. Projections indicate that Canada's...

Continue Reading
Rising Innovations Set to Propel Multilayer Varistor Market Growth

Updated Category News Views 106

Understanding the Growth of the Multilayer Varistor Market The multilayer varistor market is on the brink of an impressive expansion. With a projected market value rising from approximately US$ 0.5 billion to US$ 1.1 billion by the end of the forecast period, it reflects an estimated compound annual growth rate (CAGR) of 6.9%. This growth is largely spurred by increasing...

Continue Reading
Public Opinion Insights Revealed in Kansas Speaks Survey

Updated Category News Views 269

2025 Kansas Speaks Survey Highlights Public Sentiment The Docking Institute of Public Affairs has conducted the annual Kansas Speaks Survey, which captures the voices of the Kansas populace on critical issues. This year, a diverse panel of 526 adult residents was engaged in online discussions to share their thoughts on a variety of topics affecting their daily lives....

Continue Reading
JP Morgan's $50 Million Debut on Solana's Blockchain Era

Updated Category News Views 129

JP Morgan Embraces Blockchain Technology JP Morgan Chase & Co (NYSE: JPM) has recently embarked on a transformative journey by issuing $50 million in U.S. commercial paper directly on the innovative Solana (CRYPTO: SOL) blockchain. This significant move is not just a financial transaction; it symbolizes a pivotal moment in the adoption of blockchain technology by major...

Continue Reading
Reddit Inc Sees Notable Stock Surge Following Trading Alerts

Updated Category News Views 341

Reddit Inc Experiences Remarkable Stock Movements Reddit Inc (NYSE: RDDT) recently captured attention in the financial markets as it experienced a significant Power Inflow alert. This alert is not just a passing moment but a critical bullish signal that traders closely monitor, as it provides insights into order flow analytics from both institutional and retail investors....

Continue Reading